{"nctId":"NCT00645671","briefTitle":"Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery","startDateStruct":{"date":"2008-03"},"conditions":["Ocular Inflammation"],"count":400,"armGroups":[{"label":"Loteprednol Etabonate","type":"EXPERIMENTAL","interventionNames":["Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment"]}],"interventions":[{"name":"0.5% Loteprednol Etabonate Ophthalmic Ointment","otherNames":[]},{"name":"Vehicle of Loteprednol Etabonate Ophthalmic Ointment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subjects who are candidate for routine, uncomplicated cataract surgery\n2. Subjects who, in the Investigator's opinion, have potential postoperative pinholed Snellen visual acuity (VA) of at least 20/200 in the study eye.\n\nExclusion Criteria:\n\n1. Subjects who will require concurrent ocular therapy with NSAIDs, mast cell stabilizers, antihistamines, decongestants, or immunosuppressants (e.g., Restasis), or with ocular or systemic corticosteroids\n2. Subjects who have known hypersensitivity or contraindication to the study drug(s) or their components\n3. Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the non-study eye\n4. Subjects who have had ocular surgery (including laser surgery) in the study eye within 3 months or in the fellow eye within 2 weeks prior to the Screening Visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.","description":"A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \\>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects With Complete Resolution of Anterior Chamber Cells and Flare. At Each Follow-up Visit.","description":"A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \\>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare","description":"A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \\>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.08"},{"groupId":"OG001","value":"-0.4","spread":"1.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.31"},{"groupId":"OG001","value":"-0.7","spread":"1.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"1.37"},{"groupId":"OG001","value":"-0.9","spread":"1.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.45"},{"groupId":"OG001","value":"-1.1","spread":"1.95"}]}]}]},{"type":"PRIMARY","title":"Grade 0 for Pain","description":"Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":201},"commonTop":["Anterior chamber inflammation","Photophobia","Eye pain","Iritis","Conjunctival hyperemia"]}}}